BETHESDA, MD – March 26, 2015 – Precision for Medicine (www.precisionformedicine.com) today announced the PATH™ analytics platform, a unique tool that can identify, analyze, and provide novel scientific insights about important biomarkers, transforming traditional therapies into personalized therapeutics. PATH™ accelerates the research process, enabling a more streamlined framework for stratifying patient populations.
The emergence of cost-efficient, high-throughput biomarker assays has brought big data-driven solutions to the forefront of healthcare. While scientific advancements have inspired the big data era of precision medicine, traditional analytics tools are not advancing at the same pace. As a result, the challenges facing R&D teams to advance precision medicine efforts have largely been unanswered – motivating Precision to develop PATH™ from the ground up to address the specific needs of precision medicine programs.
PATH™ uses advanced Bayesian analytics and real-time data exploration to harness the power of next-generation technologies, such as NGS, microarrays, and multiplex assays for biomarker discovery and patient stratification. PATH™ lets users interact with large datasets in real time to gain visual insights and relevant information from genome browsers and integrated public and proprietary databases. This allows for a multiplicity of uses such as exploring “what if” scenarios to uncover the potential of patient subgroups.
“Researchers must be able to accelerate the process of translating big data into actionable clinical information. Identifying biomarkers significantly impacting aspects such as treatment response and disease severity, and exploring data in real time, will significantly advance the understanding of the link between complex biomarker data and treatment response,” said Dr. Scott Marshall, managing director analytics, Precision for Medicine. “PATH™ is another example of the work Precision for Medicine is doing to help life sciences companies successfully navigate the challenges that occur in the development and commercialization of personalized biopharmaceutical products.”
Using PATH™, pharmaceutical companies can develop patient stratification strategies to accelerate entry to the market, create market differentiation, and increase the overall value of an asset. Specifically, the PATH™ Analytics Platform helps teams:
- Identify biomarkers impacting drug response, disease severity, prognosis, and overall diagnostic abilities
- Integrate data from multiple biological assay platforms
- Estimate patient-specific biomarker signatures
- Classify patient populations and develop personalized medicine strategies
- Compare clinical effects in real time
- Optimize biomarker validation/replication efforts
- Aid in decision support
- Facilitate interactive data visualization
The PATH™ analytics platform provides an integrated and seamless view of complex biomarker data. The tool embodies a method for conducting analysis using a structured framework and approach to generate valuable and actionable insights to healthcare executives and is scalable and customizable to an organization’s needs.
About Precision for Medicine
Precision for Medicine is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization. The company is headquartered in Bethesda, MD. Visit www.precisionformedicine.com for more information.
# # #
Precision for Medicine Media Relations
212-686-2650, ext. 3027